Abstract
A phase II study of AMSA in previously treated patients with metastatic malignant melanoma was conducted. The dose schedule of AMSA was 40 mg/m2/day for 3 days repeated at 3-week intervals. Among the 30 evaluable patients, one achieved a complete response, one a partial response, and four had minor responses. Side effects included mild nausea and vomiting and moderate degree of myelosuppression. AMSA has poor activity against previously treated metastatic melanoma.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aminoacridines / administration & dosage
-
Aminoacridines / therapeutic use*
-
Aminoacridines / toxicity
-
Amsacrine
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Humans
-
Male
-
Melanoma / drug therapy*
-
Middle Aged
-
Neoplasm Metastasis
-
Skin Neoplasms / drug therapy*
Substances
-
Aminoacridines
-
Antineoplastic Agents
-
Amsacrine